Building towards precision medicine
A better understanding of molecular events underlying cancer progression drives advancements in oncology. Relevant biomarker detection is necessary to determine the optimal strategies in cancer prevention and care. However, identifying the right tools to make biomarker profiling effortless is challenging. Our comprehensive portfolio makes it easy for you to access valuable insights. From sample collection to data interpretation – we provide the most robust technologies and resources to help you detect, analyze and validate relevant biomarkers. We continuously strive to innovate and expand the range of solutions we offer, further paving the path to precision medicine.Latest insights – new solutions, events and more
-
New - DNA damage response (DDR) solutionsBe the first to learn about our new homologous recombination repair (HRR) panels that deliver valuable insights into the DNA damage repair pathway. Ready to explore? -
Oncohematology Summit – educational eventExplore the full session lineup on demand! Get the latest on new advances in oncohematology diagnostic testing and clinical research. -
Your partner in oncohematologyWe support your path to personalized blood cancer care and molecular research advancements with our comprehensive Sample to Insight solutions. -
Webinar: CDx commercializationJoin three international experts in our live webinar and discover how to prepare for successful CDx commercialization. Learn how to set up CDx testing in time for drug launch and Day-One patient access. -
The power of oneComprehensive genomic profiling (CGP) is dramatically changing our understanding of many cancers. Our multimodal technology can maximize insights by simultaneously preparing DNA and RNA libraries from a single total nucleic acid sample.
icon-oncology
Want to learn more about our oncology portfolio?
Our Sample to Insight solutions make it easy to access valuable biomarker information.
Inspiration from the lab
Professor Sue Branford is Head of the Leukaemia Lab in the Department of Genetics and Molecular Pathology at SA Pathology. She is a National Health and Medical Research Council Research Fellow and leads the International Chronic Myeloid Leukaemia Genomics Alliance. Learn about her journey and outstanding accolades, and her contributions to fighting blood cancer.
In-focus – relevant biomarkers and molecular signatures
-
PIK3CA status mattersWant to detect actionable mutations in PIK3CA? Use our test to identify breast cancer patients that may be eligible for treatment with PIQRAY. -
Confidently detect FGFR mutationsLearn about our solution to confidently assess genomic alternations in the FGFR3 gene in bladder cancer.
Testimonials from our global lab partners
-
"The Quest/QIAGEN partnership has allowed us to provide rapid and insightful information to our clinical colleagues, allowing us to better take care of their patients."Dr. Frederick K. Rocke, Medical Director of Hematology/Oncology and Coogulation, Quest Diagnostics -
"PIK3CA is the perfect example of how things should be done. All parties were optimally aligned to have the new test validated according to the very rigorous FDA standards."Dr. Lawrence Weiss, Chief Medical Officer, NeoGenomics
icon-oncology
Explore our Cancer Research Hub.
Accelerate your journey to insights and help conquer cancer.
Featured resources – information to support your work
-
Real-world lab experienceOur scientists continue to find innovative oncohematology solutions supporting labs throughout the world. Read our real-world lab experience and get advice to overcome workflow challenges and maximize blood cancer insights with fewer resources. -
Expert webinars at your fingertipsWant advice to overcome typical workflow challenges? Access our on-demand webinars that reveal useful tips and tricks and advice from the experts. Learn how our NGS solutions were able to support their research. -
One simple workflow for lung cancer profilingWant a panel to deliver comprehensive coverage of known and novel fusions as well as all relevant alterations? Our QIAseq Lung Multimodal Panel starts with total nucleic acids (DNA + RNA) and prepares targeted DNA and RNA libraries using a one-day, consolidated workflow.